Business
Voyager Therapeutics Announces Positive Preclinical Data from New Vectorized anti-HER2 Antibody Program at the 26th Society for Neuro-Oncology Annual Meeting
Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor
About this update from Voyager Therapeutics, Inc.
[{"type":"text","content":"Novel intravenous (IV) vectorized antibody approach designed to activate innate immune system, destroy metastatic breast cancer tumors, and inhibit tumor progression in CNS Proprietary TRACER™ capsid screening technology enables broad expression of vectorized antibody in mouse brain TRACER AAV vector encoding anti-HER2 antibody demonstrated tumor reduction across multiple mouse models and survival benefit CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) platform technologies, today will present preclinical data demonstrating that IV dosing of a proprietary AAV vector identified by the TRACER™️ screening technology, encoding an anti-HER2 antibody payload, prevented tumor growth in models of HER2+ brain metastases. Dan R. Laks, Ph.D., Voyager Scientist II, will present key findings at 4:15 p.m. ET during the 26th Society for Neuro-Oncology (SNO) Annual Meeting. “Today’s findings demonstrate that AAV gene transfer of HER2-directed antibodies to the central nervous system shows promise to treat brain metastases in patients with HER2+ breast cancer,” said Glenn Pierce, M.D., Ph.D., interim chief scientific officer of Voyager. “While approved anti-HER2 therapies are effective for peripheral disease, they have limited ability to reach the CNS in sufficient concentrations to treat brain metastases. By using a proprietary, TRACER AAV capsid to deliver Voyager’s vectorized payload, and by utilizing brain cells to produce therapeutic antibodies, we have demonstrated a durable effect against CNS tumors in several mouse models. We look forward to continued optimization of this innovative gene therapy approach as we progress toward clinical development.” Voyager’s vectorized anti-HER2 antibody was shown to inhibit proliferation and promote antibody-dependent cell cytotoxicity (ADCC), a process that recruits natural killer cells, macrophages and/or brain-resident innate immune cells called microglia to eliminate tumor cells. IV administration of a proprietary AAV vector incorporating a TRACER blood-brain barrier penetrant capsid and a payload encoding an ADCC enhanced anti-HER2 antibody conferred a survival benefit in a mouse model of HER2+ brain metastasis. SNO Oral Presentation DetailsTitle...